Product Overview
Composition
1 ml of the drug contains:
Active substance:
chondroitin sodium sulfate 100 mg
Excipients :
benzyl alcohol 9 mg,
sodium disulfite 1 mg,
1 M sodium hydroxide solution to pH 6.0 - 7.5,
water for injection up to 1 ml.
pharmachologic effect
Has chondrostimulating, regenerating, anti-inflammatory and 2 analgesic effects. Chondroitin sulfate is involved in the construction of the basic substance of cartilage and bone tissue.
Possesses chondroprotective properties, enhances metabolic processes in hyaline and fibrous cartilage, subchondral bone; inhibits enzymes that cause degeneration (destruction) of articular cartilage; stimulates the production of proteoglycans by chondrocytes. It helps to reduce the release of inflammatory mediators and pain factors into the synovial fluid, suppresses the secretion of leukotrienes and prostaglandins.
Slows down the resorption of bone tissue and reduces calcium loss, accelerates the processes of bone tissue regeneration. Chondroitin sulfate slows down the progression of osteoarthritis and osteochondrosis.
Promotes the restoration of the articular bag and cartilaginous surfaces of the joints, prevents the collapse of connective tissue, normalizes the production of joint fluid.
When using the drug, pain decreases and the mobility of the affected joints improves, while the therapeutic effect persists for a long time after the end of the course of therapy.
In the treatment of degenerative changes in the joints, accompanied by secondary synovitis, the effect is observed after 2-3 weeks from the start of the course. Structurally similar to heparin, it can potentially prevent the formation of fibrin thrombi in the synovial and subchondral microvasculature.
Indications
Degenerative-dystrophic diseases of the joints and spine: osteoarthritis and osteochondrosis of the spine. To accelerate the formation of callus in fractures.
Application during pregnancy and lactation
It is not recommended to use the drug during pregnancy.
During treatment, breastfeeding should be discontinued due to lack of data.
Contraindications
- hypersensitivity to the drug or its components;
- bleeding, tendency to bleeding;
- thrombophlebitis;
- children under 18 years of age (efficacy and safety have not been established).
With care No data.
- bleeding, tendency to bleeding;
- thrombophlebitis;
- children under 18 years of age (efficacy and safety have not been established).
With care No data.
Side effects
Allergic reactions (pruritus, rash, erythema, urticaria, dermatitis, edema); bleeding at the injection site
Interaction
It is possible to enhance the action of indirect anticoagulants, antiplatelet agents, fibrinolytics.
How to take, course of administration and dosage
Intramuscularly, 100 mg every other day.
With good tolerance, the dose is increased to 200 mg, starting with the fourth injection.
The course of treatment is 25-35 injections.
If necessary, a second course of treatment is possible after 6 months.
Overdose
Currently, no cases of overdose of chondroitin sulfate have been reported.
Special instructions
When the drug is used together with indirect anticoagulants, antiplatelet agents, fibrinolytics, more frequent monitoring of blood coagulation indicators is required.
In the event of allergic reactions or hemorrhages, treatment should be discontinued.
To achieve a stable clinical effect, at least 25 injections of the drug are required, but the effect persists for a long time for several months after the end of the course of treatment.
To prevent exacerbations, repeated courses of treatment are indicated.
Release form
Transparent or slightly opalescent, colorless or slightly colored liquid with a benzyl alcohol odor.
Storage conditions
At a temperature not higher than 25 ºÐ¡.
Keep out of the reach of children
Shelf life
2 years. Do not use after the expiration date!
